# BPC-157 TB-500 Dosage: Preclinical Ranges, Routes, and the Half-Life Record > BPC-157 TB-500 dosage in the research record: the per-body-weight rodent doses each peptide was studied at, the routes used, the half-life data, and why no validated blend dose exists. We report what was administered, to which species, by which route. There is no human dosing here, and no validated dose for the combination, because no controlled study has set one. ## BPC-157 and TB-500 Dosage Ranges in Preclinical Studies BPC-157 TB-500 dosage is best understood as two separate preclinical records, because there is no validated dose for the blend. Commercial research-product labeling commonly pairs the two at fixed combined masses per vial — for example roughly 10 mg BPC-157 with 10 mg TB-500, or a 20 mg combined vial — but no peer-reviewed combination dose-finding study exists [8]. Those vial numbers are packaging conventions, not validated doses. At the component level, doses are expressed per body weight in animals. BPC-157 rodent studies frequently use about 10 microg/kg and 10 ng/kg; the transected-tendon work used 10 microg/kg or 10 ng/kg intraperitoneally [1]. Gastric-ulcer cytoprotection has been studied at 400-800 ng/kg in rats. For TB-500 and its parent protein the range is wide: 2-18 mg/kg intraperitoneal in a rat embolic-stroke dose-response study (with the modeled optimum near 3.75 mg/kg and 18 mg/kg giving no benefit), and 150 microg twice weekly for 6 months in the mdx muscular-dystrophy study [6]. Higher was not better in either, which undercuts "loading" rationales. These are research doses in animals. They are not, and must not be read as, instructions for human use of either peptide or the blend. ## What Is the Half-Life of BPC-157 and TB-500? No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog pharmacokinetic study. Human intravenous full-length Thymosin Beta-4 has shown dose-proportional pharmacokinetics, but no specific half-life is established for the TB-500 heptapeptide itself [7]. In practical terms, the pharmacokinetics that would let anyone reason about timing for the combination simply have not been characterized in humans. ## Routes Studied in the Component Literature When people search for a "wolverine injection," what the literature actually documents is a set of routes used in research, not a human administration protocol. In the underlying rodent efficacy studies, both peptides were most often given intraperitoneally [1][6]. Other routes appear across the component literature: subcutaneous and intramuscular (the predominant research-community routes for the blend, not from controlled human efficacy trials), intravenous (the human Phase 1 work on full-length Thymosin Beta-4, and a BPC-157 IV safety pilot), and local or topical routes in individual-compound wound and tendon models. Which route was used matters for interpreting a result — an intraperitoneal rodent dose does not translate into a human subcutaneous one — which is another reason the blend cannot be "dosed" from this record. ## Oral vs. Parenteral Administration in Preclinical Models On the question of bpc 157 tb 500 oral use: BPC-157 is often described as a "stable gastric" peptide and has been studied via peroral routes in animal models, which is why oral framing attaches to it more readily than to most peptides. TB-500 efficacy data, by contrast, come overwhelmingly from parenteral (mostly intraperitoneal) dosing of full-length Thymosin Beta-4 [6][7]. Oral blend products are marketed, but they lack validated pharmacokinetics — there is no human oral PK for the combination, so an oral "dose" cannot be characterized from the published record. ## Reconstitution and Product-Identity Notes Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. A common practice is to reconstitute the two peptides separately or in a shared vial. Two identity caveats sit on top of this. First, in unregulated material the product identity, purity, and actual BPC-157:TB-500 ratio are not guaranteed. Second, "TB-500" as sold is the Ac-LKKTETQ heptapeptide (~889 Da), while most of the efficacy data attributed to it were generated with full-length Thymosin Beta-4 (~4963 Da) [7] — so the label and the evidence base do not fully line up. None of this is dosing guidance; it is context for reading the research. For where the studies stop and the cautions begin, see [half-life and routes studied](/dosage) and the [long-term safety and tolerability](/side-effects) page. --- A pastel night-sketchbook of the BPC-157 and TB-500 record — each peptide doodled gently against its own studies, the untested combination left as a blank page, and the FDA 503A status drawn in before anything else; no clinic behind the notebook and nothing here dispensed or sold.